SCHEMBL16828014

SCHEMBL16828014

CCOC(=O)N1CCC(NC(=O)c2ccc(Cl)cc2)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.78
KDM4E B2RXH2 2/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
HSD17B10 Q99714 2/20 0.59
TP53 P04637 2/20 0.59
HPGD P15428 1/20 0.59
CASP1 P29466 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
ENPP2 Q13822 1/20 0.59
PLG P00747 1/20 0.59
PRSS1 P07477 1/20 0.59
PRSS2 P07478 1/20 0.59
PRSS3 P35030 1/20 0.59
ST14 Q9Y5Y6 1/20 0.59
CHRM2 P08172 1/20 0.59
CHRM5 P08912 1/20 0.59
CHRM3 P20309 1/20 0.59
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
ALOX15 P16050 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12301984 0.90 ALDH1A1 (0.63) ALDH1A1KDM4ESMN1; SMN2HSD17B10TP53
SCHEMBL16314532 0.87 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2HSD17B10TP53
SCHEMBL7532504 0.84 HDAC4 (0.60) ALDH1A1KDM4ESMN1; SMN2NPSR1ENPP2
SCHEMBL12010061 0.83 ALDH1A1 (0.58) ALDH1A1KDM4ESMN1; SMN2HSD17B10TP53
SCHEMBL11457429 0.82 KDM4E (0.63) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL28801747 0.81 CHRNA7 (0.57) ALDH1A1KDM4ESMN1; SMN2NPSR1TSHR
SCHEMBL10107498 0.80 ALDH1A1 (0.58) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL4966815 0.80 ALDH1A1 (0.55) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL3451539 0.80 DRD2 (0.58) ALDH1A1KDM4ESMN1; SMN2TP53MEN1
SCHEMBL3451543 0.80 DRD2 (0.58) ALDH1A1KDM4ESMN1; SMN2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083591-B1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2018-01-03 EP disclosed
US-9751861-B2 N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase MERCK PATENT GMBH (DE) 2017-09-05 US disclosed
US-9751861-B2 N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase MERCK PATENT GMBH (DE) 2017-09-05 US disclosed
US-9751861-B2 N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase MERCK PATENT GMBH (DE) 2017-09-05 US disclosed
US-20160311798-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2016-10-27 US disclosed
US-20160311798-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2016-10-27 US disclosed
US-20160311798-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2016-10-27 US disclosed
EP-3083591-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE Merck Patent GmbH (DE) 2016-10-26 EP disclosed
WO-2015090496-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2015-06-25 WO disclosed
WO-2015090496-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311798-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE PDK1, PDK3, PDK2 ALDH1A1 109/4885KDM4E 1016/4885SMN1; SMN2 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.